Jun 28 2007
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
Ondansetron hydrochloride tablets, the generic equivalent of GlaxoSmithKline's Zofran(R) tablets, will be available in 4 mg and 8 mg strengths. Ondansetron hydrochloride tablets are indicated for prevention of nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery.
Annual sales of Ondansetron hydrochloride tablets in the U.S. were approximately US$746 million for the twelve months ending March 2007 according to IMS Health data.
http://www.actavis.com/